4380-55-6

Basic information

• Product Name: Deltacortinene Acetate (Predisolone Acetate IMpurity)
• Synonyms: Deltacortinene Acetate (Predisolone Acetate IMpurity);Deltacortinene Acetate;Prednisolone Acetate EP Impurity E;2-((8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
• CAS NO: 4380-55-6
• Molecular Formula: C₂₃H₂₈O₅
• Molecular Weight: 384.46542
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals, Steroids
• Mol File: 4380-55-6.mol
• Article Data: 3

Chemical Properties

• Melting Point: 222-223 °C
• Boiling Point: 556.9±50.0 °C(Predicted)
• Appearance: /
• Density: 1.25±0.1 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 12.46±0.60(Predicted)
• CAS DataBase Reference: Deltacortinene Acetate (Predisolone Acetate IMpurity)(CAS DataBase Reference)
• NIST Chemistry Reference: Deltacortinene Acetate (Predisolone Acetate IMpurity)(4380-55-6)
• EPA Substance Registry System: Deltacortinene Acetate (Predisolone Acetate IMpurity)(4380-55-6)

Safety Data

• Hazardous Substances Data: 4380-55-6(Hazardous Substances Data)

Usage

Uses

Deltacortinene Acetate is a glucocorticoid, an analog of Prednisolone (P703740), a synthetic corticosteroid; metabolically interconvertible with Prednisone (P703780).

Upstream product

• 7753-60-8 anecortave 
• 898-84-0 (8S,9S,10R,11S,13S,14S)-11-Hydroxy-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-6H-cyclopenta[a]phenanthrene-3,17-dione 
• 52-21-1 prednisolone 21-acetate 

Downstream Products

• 79-61-8 dichlorisone 21-acetate 
• 426-20-0 9-fluoro-11β,17-dihydroxy-pregna-1,4-diene-3,20-dione 
• 338-95-4 isoflupredone 
• 7008-26-6 Dichlorisone 
• 338-98-7 isoflupredone acetate 
• 382-66-1 9-fluoro-11β,17-dihydroxy-21-methanesulfonyloxy-pregna-1,4-diene-3,20-dione 
• 38680-83-0 21-acetoxy-9,11β-epoxy-17-hydroxy-9β-pregna-1,4-diene-3,20-dione 
• 37413-91-5 2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate 
• 13649-57-5 21-Deacetyldeflazacort 
• 14484-47-0 deflazacort 
• 38680-83-0 21-acetyloxy-9β,11β-epoxy-17α-hydroxy-1,4-diene-3,20-dione 
• 72498-89-6 17α, 21-diacetyloxy-9β,11β-epoxy-6α-fluoro-1,4-diene-3,20-dione 
• 2326-26-3 acetic acid 2-((6S,8S,9R,10S,11S,13S,14S)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15-decahydro-3H-cyclopenta[a]phenanthrene-17-yl)-2-oxo-ethyl ester 
• 4306-83-6 21-acetyloxy-11β,16α,17α-trihydroxy-6α,9α-difluoro-1,4-diene-3,20-dione 

Relevant articles and documents

Optimization of the synthesis of a key intermediate for the preparation of glucocorticoids

A short and efficient synthesis, based on a one-step double elimination, of a key intermediate in the synthesis of various glucocorticosteroids has been developed. This method can be carried out on large scale for further industrial applications. The synthesis allowed us to identify a novel prednisolone derivative 10 and its anti-inflammatory activity was determined in an in vivo model of inflammation. In order to understand the regioselectivity of the double elimination under various conditions, mechanistic studies were undertaken and confirmed the experimental results. We also propose a mechanism for the formation of the new steroid 10 studied by molecular modeling.

Microbial conversion of pregna-4,9(11)-diene-17α,21-diol-3,20-dione acetates by Nocardioides simplex VKM Ac-2033D

The conversion of pregna-4,9(11)-diene-17α,21-diol-3,20-dione 21-acetate (I) and 17,21-diacetate (VI) by Nocardioides simplex VKM Ac-2033D was studied. The major metabolites formed from I were identified as pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 21-acetate (II) and pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione (IV). Pregna-4,9(11)-diene-17α,21-diol-3,20-dione (III) and pregna-1,4,9(11)-triene-17α,20β,21-triol-3-one (V) were formed in minorities. Biotransformation products formed from VI were pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 17,21-diacetate (VII), pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 21-acetate (II), pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione (IV), pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 17-acetate (VIII), pregna-1,4,9(11)-triene-17α,20β,21-triol-3-one (V). The conversion pathways were proposed including 1(2)-dehydrogenation, deacetylation, 20β-reduction and non-enzymatic migration of acyl group from position 17 to 21. The conditions providing predominant accumulation of pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 21-acetate (II) from I and pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 17-acetate (VIII) from VI in a short-term biotransformation were determined.